亚洲最大无码中文字幕网站,国产清纯在线一区二区WWW,很黄很黄让你高潮视频,婷婷六月激情综合一区

beat365在線體育官網(wǎng)

College of Biological Science and Engineering

黃祖雄*

發(fā)布日期:2013-06-27 發(fā)布者:

姓名:黃祖雄

性別:

職務(wù)主任醫(yī)師/碩士生導(dǎo)師

學(xué)歷:博士

電子郵件: 2556356068@qq.com

主要研究方向:肝病與宿主免疫

教育工作經(jīng)歷:

1996/9-2001/7:  福建醫(yī)科大學(xué)臨床醫(yī)學(xué),學(xué)士

2001/9-2004/7:  福建醫(yī)科大學(xué)兒科學(xué),碩士

2004/9-2009/12福州市傳染病院感染科,住院醫(yī)師

2009/12-2016/12: 福建醫(yī)科大學(xué)孟超肝膽醫(yī)院,肝病內(nèi)科主治醫(yī)師

2011/9-2014/7: 南方醫(yī)科大學(xué),感染病學(xué)博士

                                   2016/12-至今,福建醫(yī)科大學(xué)孟超肝膽醫(yī)院肝病內(nèi)科,副主任醫(yī)師

                                   2021/9至今,beat365在線體育官網(wǎng)孟超醫(yī)學(xué)與交叉科學(xué)中心,碩士生導(dǎo)師

教學(xué)簡(jiǎn)介:


科研簡(jiǎn)介:以臨床隊(duì)列為基礎(chǔ),利用分子生物學(xué)、生物化學(xué)、細(xì)胞生物學(xué)、免疫學(xué)等技術(shù)從事肝病與宿主免疫相關(guān)的機(jī)制研究。已在Aliment Pharmacol Ther、Hepatology international、Frontiers in ImmunologyAntiverial Research等國(guó)際刊物發(fā)表SCI論文十余篇。主持國(guó)家自然科學(xué)基金項(xiàng)目1項(xiàng),省部級(jí)項(xiàng)目3項(xiàng),多項(xiàng)國(guó)家級(jí)橫向項(xiàng)目及廳局級(jí)項(xiàng)目。

社會(huì)兼職:中華醫(yī)學(xué)會(huì)肝病學(xué)分會(huì)青年委員,中華醫(yī)學(xué)會(huì)感染病學(xué)分會(huì)青年委員,中國(guó)醫(yī)師協(xié)會(huì)感染科醫(yī)師分會(huì)青年委員,福建省醫(yī)學(xué)會(huì)感染病學(xué)分會(huì)常務(wù)委員,福建省醫(yī)學(xué)會(huì)肝病學(xué)分會(huì)委員。Infectious diseases & immunity、Journal of Gastroenterology and Hepatology》 審稿人,《福建醫(yī)科大學(xué)學(xué)報(bào)》青年編委《臨床肝膽病雜志》青年編委。

科研項(xiàng)目:

1. Toll樣受體信號(hào)通路及miR-155在慢性乙型肝炎患者自然殺傷細(xì)胞功能失衡中的作用及機(jī)制研究,國(guó)家自然科學(xué)基金面上項(xiàng)目,2016/01-2020/12,編號(hào):81670532,58萬(wàn),主持。

2. 腸道菌群介導(dǎo)LPS/AMPK通路在滸苔多糖改善NAFLD肝纖維化的作用及調(diào)控機(jī)制福建省衛(wèi)生健康中青年骨干人才培養(yǎng)項(xiàng)目,2022/10-2025/10,編號(hào):2022GGA050,10萬(wàn),主持。

3. 中性粒細(xì)胞胞外誘捕網(wǎng)在慢加急性肝衰竭中的作用,福建自然科學(xué)基金面上項(xiàng)2020/11-2023/11,編號(hào): 2020J011213328萬(wàn),主持。

4. 靶向Toll樣受體8信號(hào)通路調(diào)控慢性乙型肝炎患者自然殺傷細(xì)胞功能的研究福州市衛(wèi)生健康科技計(jì)劃項(xiàng)目,2020/10-2023/10,編號(hào): 2020-S-wt4,16萬(wàn),主持。

5. 血小板ADP抑制率作為乙肝相關(guān)終末期肝病分層診斷新型標(biāo)記物的驗(yàn)證性研究,艾滋病和病毒性肝炎等重大傳染病防治科技重大專項(xiàng)2019/01-2021/12,編號(hào):2018ZX10723203-00457萬(wàn),子任務(wù)負(fù)責(zé)人

6. Toll樣受體信號(hào)通路及其下游miR-155參與慢性乙型肝炎患者自然殺傷細(xì)胞功能調(diào)控的作用及機(jī)制,福建自然科學(xué)基金面上項(xiàng)目,2015/09-2019/09編號(hào):2015J01361,8萬(wàn),主持。

已發(fā)表論文:

1. Ao Xiulan., Gan Qiaorong., Huang Xuan., Bao Dongpeng., Wu Xuwei., Lin Qiuxiang., Lin Aifang., Ding Yating., Wang Lingxia., Chen Yanping., Huang Zuxiong*.TLR8 agonist partially improves IFN-γ deficiency of NK cells in chronic hepatitis B through the synergy of monocytes. Aliment Pharmacol Ther, 2023, 57(4), 387-398. doi:10.1111/apt.17382

2. Huang Z, Wang N, Huang S, Chen Y, Yang S, Gan Q, Ye H, Liu B, Pan C. Increased Serum Soluble Urokinase Plasminogen Activator Receptor Predicts Short-Term Outcome in Patients with Hepatitis B-Related Acute-on-Chronic Liver Failure. Gastroenterol Res Pract, 2019(undefined), 3467690. doi:10.1155/2019/3467690

3. Huang Z, Ge J, Pang J, Liu H, Chen J, Liao B, Huang X, Zuo D, Sun J, Lu M, Zhang X, Hou J.Aberrant expression and dysfunction of TLR2 and its soluble form inchronic HBV infection and its regulation by antiviral therapy. Antiviral Research.2015,118(2015):10-19

4. Huang Z, Lin C, Fang J, Wang N, Zhou R, Pan C.Acute kidney injury in hepatitis B-related acute-on-chronic liver failure without preexisting liver cirrhosis. Hepatol Int.2015,9(3):416-423

5. Ge J#, Huang Z#, Liu H, Chen J, Xie Z, Chen Z, Peng J, Sun J, Hou J, Zhang X. Lower Expression of MicroRNA-155 Contributes to Dysfunction of Natural Killer Cells in Patients with Chronic Hepatitis B. Front Immunol. 2017 Sep 22;8:1173. doi: 10.3389/fimmu.2017.01173. (#共同一作)

6. Chen Y#, Huang Z#, Ma D, Chen L, Lai Q, Huang X, Zhou J, Zhang X, Ma Q, Chen Z, Zuo D. Involvement of soluble scavenger receptor A in suppression of T cell activation in patients with chronic hepatitis B.BMC Immunol. 2015,1629(#共同一作)

7. Lai Q, Ma S, Ge J, Huang Z, Huang X, Jiang X, Li Y, Zhang M, Zhang X, Sun J,Abbott WG, Hou J. TCRγδ(+)CD4(-)CD8(-) T cells suppress the CD8(+) T-cell response to hepatitis B virus peptides, and are associated with viral control in  chronic hepatitis B. PLoS One. 2014,14;9(2):e88475.

8. Chen L, Zheng CX, Lin MH, Huang ZX, Chen RH, Li QG, Li Q, Chen P. Distinct quasispecies characteristics and positive selection within precore/core gene in hepatitis B virus HBV associated acute-on-chronic liver failure. J Gastroenterol Hepatol. 2013,28(6):1040-6.

9. Liao B, Wang Z, Lin S, Xu Y, Yi J, Xu M, Huang Z, Zhou Y, Zhang F, Hou J.Significant fibrosis is not rare in Chinese chronic hepatitis B patients with persistent normal ALT. PLoS One. 2013,8(10):e78672.

10. Zhou R, Pan F, Lin C, Lin X, Gao H, Huang S, Huang Z, Lin Y, Pan C, Zhou Y. Baseline prognostic factors and statistic model to predict early virological response in lamivudine-treated patients with chronic hepatitis B. Int J Clin Exp Med. 2015,8(10):19258-65.

11. Deng G, Ge J, Liu C, Pang J, Huang Z, Peng J, Sun J, Hou J, Zhang X. Impaired expression and function of TLR8 in chronic HBV infection and its association with treatment responses during peg-IFN-α-2a antiviral therapy. Clin Res Hepatol Gastroenterol. 2017,S2210-7401(17)30005-0.

12. Lai J, Liu Y, Pan C, Lin C, Sun F, Huang Z, Lin Y, Zhou R, Lin Y, Zhou Y. Interleukin-1 receptor antagonist expression is inversely associated with outcomes of hepatitis B-related acute-on-chronic liver failure. Exp Ther Med.2017,13(6):2867-2875.



獲獎(jiǎng)情況